Specialty Pharma Journal Specialty, Precision & Technology
JUPITER, FL – November 21, 2016 – While there have been advances in the treatment of hormone-driven breast cancer, resistance to these therapies remains a significant problem. Side effects, including an increased risk of uterine cancer among postmenopausal women, also severely curtail their use for prevention. However, a new study …
Tag Archives: precision medicine
November, 2016
October, 2016
-
24 October
Study Indicates that Advances in Precision Medicine have Improved Breast Cancer Treatment
A new study examines how one early example of precision medicine–tumor genome testing–is being used in women with breast cancer to reduce overtreatment and maximize the benefits of chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that physician recommendations and final …
September, 2016
-
28 September
Pairnomix Launches Screening Services Assisting Physicians to Identify Treatments Based on Rare Genetic Mutations
MAPLE GROVE, Minn., Sept. 28, 2016 /PRNewswire/ — Pairnomix, LLC, a genetic research company and member of the Patient-Empowered Precision Medicine Alliance (PEPMA) recognized by the White House, today reported on the successful launch of its unique characterization and drug screening services that provide physicians with data on a patient’s …
-
21 September
BioNTech Enters $310 Million Personalized Cancer Vaccine Deal with Genentech
MAINZ, Germany, September 21, 2016 /PRNewswire/ –BioNTech AG, a fully integrated private biotechnology company developing personalized cancer immunotherapies, today announced that it will enter into a worldwide strategic collaboration with Genentech, a member of the Roche Group, to develop, manufacture and commercialize novel messenger RNA (mRNA)-based, individualized cancer vaccines. The …
-
15 September
Eisai Establishes AiM Institute to Discover Human Biology Driven Precision Medicines
ANDOVER, Mass., Sept. 15, 2016 /PRNewswire/ — Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has announced the launch of the Eisai Andover innovative Medicines (AiM) Institute, a discovery innovation unit within the greater Boston biopharma hub. With 90 integrated scientists at a state-of-the-art research facility in Andover, …
-
12 September
iConquerMS Initiative Launches Personalized Medicine Research in Multiple Sclerosis
WALTHAM, Mass., Sept. 12, 2016 /PRNewswire-USNewswire/ — iConquerMS™ (www.iConquerMS.org), a research initiative of the Accelerated Cure Project for Multiple Sclerosis, today launches REAL MS™, a prospective longitudinal study of multiple sclerosis intended to answer important questions about the heterogeneity of the experience of MS across the population of people living …
-
9 September
New Insights into Tumor-Infiltrating T Cells
Investigators from Brigham and Women’s Hospital have identified a distinct gene module for T cell dysfunction distinct from activation in tumor-infiltrating T cells, thus paving the way for the development of new precision therapeutics. T cell dysfunction (also called exhaustion) arises in chronic disease states such as cancer and chronic …
August, 2016
-
8 August
Allscripts’ 2bPrecise Launches a Genomics and Precision Medicine Initiative at NIH
CHICAGO, Aug. 08, 2016 (GLOBE NEWSWIRE) — 2bPrecise LLC, a wholly owned subsidiary of Allscripts Healthcare Inc. (Allscripts) (NASDAQ:MDRX), has launched a strategic early adopter program at the National Institutes of Health (NIH), America’s leading Care Institution for clinical research and a long-time Allscripts Sunrise™ client. The program will focus …
July, 2016
-
29 July
NIH-Led Researchers Develop Software that could Facilitate Drug Development
A team of researchers led by a National Institutes of Health investigator, Teresa Przytycka, Ph.D., has developed a new software tool called AptaTRACE that could be an important advance for drug developers and other scientists who want to identify molecules that bind with high precision to targets of interest. “This …
-
21 July
Precision Cancer Test Validated for Clinical Usage
A powerful next-generation genome-sequencing test developed at Weill Cornell Medicine can detect mutations that guide precision cancer treatment with over 95 percent accuracy, according to new research. The scientists say their findings, published July 20 in NPJ Genomic Medicine, validate the test, called Weill Cornell Medicine EXaCT-1, and demonstrate its …